AIM2CERV is a global, phase 3 study evaluating axalimogene filolisbac (ADXS11-001), an investigational drug being studied in women who have been diagnosed with cervical cancer.
The study is for women living with high-risk, locally-advanced cervical cancer (HRLACC) which is a cervical cancer that has an increased risk for returning following treatment with chemotherapy and radiation therapy. Your doctor can help determine if you meet the requirements for the study.
This study is being done to determine whether ADXS11-001, when taken after the completion of chemotherapy and radiation therapy, can help you live longer without the disease returning.
ADXS11-001 is an investigational product which has not been approved by the Food & Drug Administration (FDA).